Left ventricular hypertrophy: Should it be reduced?

Left ventricular hypertrophy: why does it happen?

Patients with end-stage renal disease (ESRD) have much higher rates of cardiovascular disease than the healthy population. Left ventricular hypertrophy (LVH), in particular, is common in this patient group. The impact of a decline in haemoglobin concentration on left ventricular mass index has been well documented. Partial correction of anaemia with recombinant human erythropoietin (epoetin) tr...

Left ventricular hypertrophy: is it really?

Background Patients with left ventricular hypertrophy (LVH), typically assessed by 2D echocardiography, are at a greater risk for heart failure and sudden cardiac death. An accurate diagnosis of LVH is essential to clinical evaluation and treatment. However, 2D echo has inferior spatial resolution and less than optimal measurement positioning, relative to cardiac MRI. This “real-world” study, b...

Should the contribution of ACE gene polymorphism to left ventricular hypertrophy be reconsidered?

Regression of left ventricular hypertrophy: should we echo echo?

I n the current issue, the study of Pierdomenico et al.1 showed that regression of left ventricular hypertrophy (LVH) after two year’s antihypertensive treatment was accompanied by a reduced risk of cardiovascular events independently of the ambulatory blood pressure during treatment. This further supports the value of using LVH regression as a surrogate end-point for morbid events in hypertens...

Left Ventricular Hypertrophy Familial Predisposition of Left Ventricular Hypertrophy

METHODS Echocardiographic and anthropometric measurements were performed in 2,293 individuals who participated in the echocardiographic substudies of population-based MONICA Augsburg surveys. In addition, a total of 319 siblings of survey participants with echocardiographic evidence of LVH were evaluated. The risk of these siblings to present with LVH or abnormal LV geometry was estimated by co...